To amend the Federal Food, Drug, and Cosmetic Act to allow for the approval of an abbreviated new drug application submitted by a subsequent applicant in the case of a failure by a first applicant to commence commercial marketing within a certain period, and for other purposes.
H.R. 1051
This bill modifies provisions related to market exclusivity for a generic drug.
Learn about this bill’s status and read its full summary in the Pocket Congress app.
Open in the Pocket Congress app 
Scan to open this page in Pocket Congress